Answer
The mean terminal half-life of canakinumab in adults with cryopyrin-associated periodic syndromes (CAPS) was 26 days following a single 150 mg subcutaneous dose.
Sources for this answer
- Ilaris 150mg/ml Solution for InjectionNovartis Pharmaceuticals UK Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 8Document updated
Sources checked